Safety and immunogenicity of a SARS-CoV-2 recombinant protein subunit vaccine adjuvanted with Alum + CpG 1018 in healthy Indonesian adults: A multicenter, randomized, comparative, observer-blind, placebo-controlled phase 2 study.
Maddeppungeng M, Nurdin A, Nency YM, Sekartini R, Medise BE, Soedjatmiko S, Massi MN, Darma S, Darussalam AHE, Ramadhani N, Hidayah N, Chalid MT, Ramadany S, Wahyuni S, Djaharuddin I, Santoso A, Fikri B, Alimuddin S, Pelupessy NM, Masadah R, Putri AZ, Setyaningsih L, Yani FF, Anggrainy F, Deza PA, Maharani N, Mahati E, Hapsari R, Farhanah N, Pramudo SG, Tri Anantyo D.
Maddeppungeng M, et al. Among authors: santoso a.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2429231. doi: 10.1080/21645515.2024.2429231. Epub 2024 Dec 5.
Hum Vaccin Immunother. 2024.
PMID: 39632708
Free PMC article.
Clinical Trial.